We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov Menu

Minimum Alveolar Concentrations of Sevoflurane for Maintaining Bispectral Index Below 50 in Morbidly Obese Patients

The recruitment status of this study is unknown. The completion date has passed and the status has not been verified in more than two years.
Verified December 2013 by Ahed ZEIDAN, Procare Riaya Hospital.
Recruitment status was:  Recruiting
ClinicalTrials.gov Identifier:
First Posted: July 6, 2011
Last Update Posted: December 3, 2013
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by (Responsible Party):
Ahed ZEIDAN, Procare Riaya Hospital
the target of this study is to assess the minimum alveolar concentration of sevoflurane to maintain theBispectral Index below 50.The minimum alveolar concentration (MAC) for maintaining Bispectral Index below 50 (MACBIS50) of sevoflurane has been reported previously in adult with Body Mass Index ( BMI) < 40 to be 0.97 and in enfant to be 2.83%, However, there is no study assessed theBispectral Index below 50 (MACBIS50 ) in morbidly obese patient (BMI > 40). The first aim of our study is to assess the MACBIS50 of sevoflurane in morbidly obese patients BMI 40 - 70 using the Continuous Reassessment Method (CRM) in 80 % of patients.


Study Type: Observational
Study Design: Observational Model: Case-Only
Time Perspective: Prospective
Official Title: Minimum Alveolar Concentrations of Sevoflurane for Maintaining Bispectral Index Below 50 in Morbidly Obese Patients

Resource links provided by NLM:

Further study details as provided by Ahed ZEIDAN, Procare Riaya Hospital:

Primary Outcome Measures:
  • Minimal alveolar concentration of Sevoflurane for Maintaining BIS Below 50 [ Time Frame: 24 hours ]

Biospecimen Retention:   None Retained
Bisbectral index (BIS)

Estimated Enrollment: 30
Study Start Date: June 2011
Estimated Study Completion Date: December 2013
Estimated Primary Completion Date: December 2013 (Final data collection date for primary outcome measure)
Morbidly obese patients
BMI 40-50 k/m2
Morbidly obese
BMI 50-60 k/m2
Morbidly obeses
BMI 60-70 k/m2

Detailed Description:

After ethical committee approval and written informed consent, 30 morbidly obese adult patients , BMI 40- 70Kg/m², ASA physical status 1 and 2 , aged 18-49 yr, , undergoing elective bariatric surgery under general anesthesia using sevoflurane, were included in this study.

Monitoring consisted of noninvasive blood pressure, Electrocardiogram (ECG) , pulse oximetry, and BIS. All subjects received a standard dose of 2 mcg/kg fentanyl approximately 20 min before induction of general anesthesia. a standard BIS® monitor strip was applied before fentanyl administration and induction of general anesthesia. Induction was performed in all patients with 2m/kg propofol, 0.2 mg/kg cisatracuruim, followed by direct laryngoscopy and tracheal intubation. Therefore, when BIS reached > 65 , sevoflurane was started immediately at the predetermined dose.

The endtidal sevoflurane concentration was adjusted with starting dose for the first cohort patients 1% and maintained for 10 min to ensure equilibration with the cerebral anesthetic partial pressure followed by a 1-min assessment of BIS taken at 10-s intervals. Briefly, a first dose is given to the first patient and the next doses are given according to the following rule: if the subject responds positively (BIS<50), the dose is decreased one step for the next subject, and conversely, if the subject does not respond (BIS>50), the dose is increased one step. The dose adjustment is 0.2% for sevoflurane. The CRM is used to calculate the dose adjustment for every cohort with the number of patients for every cohort .


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   20 Years to 40 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population
Morbidly obese patients weighting BMI 40-70 k/m2

Inclusion Criteria:

  • morbidly obese patient
  • BMI 40-70
  • age : 20-40 year

Exclusion Criteria:

  • Age< 20 and > 40
  • BMI < 40 and > 70
  • comorbidity
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01388296

Contact: Ahed ZEIDAN, MD 009615409107 doczeidan@hotmail.com

Saudi Arabia
Procare Riaya Hospital Recruiting
Al Khobar, Estern, Saudi Arabia, 3
Contact: kamal Abdulkhalek, MD    00966505814754    Kamal.abdulkhaleq@procare.com.sa   
Sponsors and Collaborators
Procare Riaya Hospital
Study Chair: Ahed ZEIDAN, MD Procare Riaya Hospital
  More Information

Responsible Party: Ahed ZEIDAN, MD, Procare Riaya Hospital
ClinicalTrials.gov Identifier: NCT01388296     History of Changes
Other Study ID Numbers: PRH 03
First Submitted: June 30, 2011
First Posted: July 6, 2011
Last Update Posted: December 3, 2013
Last Verified: December 2013

Additional relevant MeSH terms:
Platelet Aggregation Inhibitors
Anesthetics, Inhalation
Anesthetics, General
Central Nervous System Depressants
Physiological Effects of Drugs